Performance analysis of Galectin Therapeutics (GALT)
Annual Return
Over the past 3 years, GALT has had an average annual return of +14.41%, underperforming the benchmark SPY, which returned +22.45% annual.
Over the past 5 years, GALT has had an average annual return of -9.42%, underperforming the benchmark SPY, which returned +13.88% annual.
Over the past 10 years, GALT has had an average annual return of +5.02%, underperforming the benchmark SPY, which returned +15.45% annual.
Since Sep 9, 2002, GALT has had an average annual return of -6.64%, underperforming the benchmark SPY, which returned +11.36% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.52% | +222.51% | -22.27% | +46.82% | -45.39% | -7.61% | -21.65% | -16.62% | +2.69% | +240.64% | -40.23% | -52.73% |
| 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
| -57.05% | +294.20% | -64.42% | +6.67% | +221.43% | +211.11% | -87.14% | +55.56% | -85.25% | +22% | -36.71% | +35.74% |
| 2002 | |||||||||||
| +45.50% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -31.99% | +5.30% | -6.36% | -18.62% | +10.99% | -6.76% | -43.52% | ||||||
| 2025 | -3.07% | +25.53% | -22.25% | +12.29% | -4.38% | +60.99% | +72.53% | +17.61% | -1.07% | +37.21% | -1.38% | -27.39% | +222.51% |
| 2024 | +1.81% | +15.70% | +22.28% | +46.84% | -22.50% | -16.94% | +10.62% | +7.83% | +2.05% | -10.21% | +17.01% | -55.36% | -22.27% |
| 2023 | +2.65% | +78.39% | +1.45% | -16.17% | -10.84% | -8.26% | +4.17% | +16.64% | +9.74% | +6.25% | -4.41% | -14.89% | +46.82% |
| 2022 | -6.78% | -3.11% | -13.86% | -3.73% | -16.80% | +1.58% | +72.44% | -15.93% | -14.21% | -15.32% | -8.00% | -10.96% | -45.39% |
| 2021 | -12.53% | +14.33% | -3.16% | +103.71% | -10.18% | -19.38% | -14.06% | +42.89% | -1.28% | -18.28% | -17.03% | -21.30% | -7.61% |
| 2020 | -8.02% | -19.39% | -7.58% | +26.82% | +21.92% | +0.99% | -14.71% | +1.52% | +0.77% | -4.85% | +2.36% | -13.84% | -21.65% |
| 2019 | +41.11% | +7.66% | -1.93% | -16.23% | -5.86% | +2.98% | -10.84% | -9.99% | +10.20% | +8.47% | -18.84% | -11.48% | -16.62% |
| 2018 | +38.05% | -10.85% | +15.33% | -29.75% | +52.54% | +25.21% | -20.60% | +28.14% | -7.12% | -28.27% | +14.62% | -30.58% | +2.69% |
| 2017 | +0.98% | +91.88% | +21.10% | +33.02% | -25.80% | +8.35% | -18.68% | -14.04% | +24.42% | +14.53% | -3.67% | +41.48% | +240.64% |
Drawdown analysis of Galectin Therapeutics (GALT)
The maximum drawdown for the GALT was -99.02%, occurring on Nov 17, 2008. This drawdown has not yet recovered.
The current GALT drawdown is -93.62%.
Since Sep 9, 2002 GALT has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.02% | Sep 11, 2003 | 1306 | Nov 17, 2008 | Ongoing | Ongoing | Ongoing |
| -34.29% | Sep 12, 2002 | 178 | May 29, 2003 | 11 | Jun 13, 2003 | 189 |
| -15.96% | Jul 2, 2003 | 24 | Aug 6, 2003 | 23 | Sep 9, 2003 | 47 |
| -5.00% | Jun 13, 2003 | 1 | Jun 16, 2003 | 3 | Jun 19, 2003 | 4 |
| -3.46% | Jun 19, 2003 | 1 | Jun 20, 2003 | 2 | Jun 24, 2003 | 3 |
| -2.20% | Jun 26, 2003 | 1 | Jun 27, 2003 | 3 | Jul 2, 2003 | 4 |